Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pfizer's $43 billion takeover of Seagen would reshape the oncology pipeline of one of the world's largest drugmakers, bringing in four marketed cancer drugs…
Pfizer Inc said on Monday it would buy U.S. biotech Seagen for $43 billion to boost its cancer portfolio and offset a steep fall in COVID-19 related sales and…
Post-close (Q4 2023 earnings): CEO Albert Bourla calls Seagen a 'big bet in this technology,' reaffirms ~$3.1B anticipated Seagen revenue in 2024 guidance and…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Pfizer acquired Seagen for approximately $43 billion ($229 per share in cash), gaining Seagen's world-leading antibody-drug conjugate (ADC) technology platform, four marketed oncology medicines (Adcetris, Padcev, Tivdak, Tukysa), and eleven pipeline candidates. The deal doubled Pfizer's oncology pipeline and positioned the company to generate over $10 billion in risk-adjusted oncology revenues by 2030.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Seagen Inc. (this deal) | 2023 | $43.0B | 77 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2023 deals · Pfizer Inc. deals · Oncology deals